For research use only. Not for therapeutic Use.
(±)-BAY-1251152（Cat No.:I019847）is a potent and selective inhibitor of cyclin-dependent kinase 9 (CDK9), a key regulator of transcription elongation in cells. By inhibiting CDK9, this compound disrupts RNA synthesis, particularly in cancer cells where transcription is highly active, leading to apoptosis and cell death. (±)-BAY-1251152 is studied for its potential in treating various cancers, including hematological malignancies and solid tumors. Its ability to target transcriptional dependencies in cancer cells makes it a promising candidate in developing therapies aimed at disrupting tumor growth and survival.
| Catalog Number | I019847 |
| CAS Number | 1610358-53-6 |
| Molecular Formula | C₁₉H₁₈F₂N₄O₂S |
| Purity | ≥95% |
| Target | CDK |
| Storage | Store at -20°C |
| IUPAC Name | 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-[4-[(methylsulfonimidoyl)methyl]pyridin-2-yl]pyridin-2-amine |
| InChI | InChI=1S/C19H18F2N4O2S/c1-27-17-8-13(20)3-4-14(17)15-9-19(24-10-16(15)21)25-18-7-12(5-6-23-18)11-28(2,22)26/h3-10,22H,11H2,1-2H3,(H,23,24,25) |
| InChIKey | YZCUMZWULWOUMD-UHFFFAOYSA-N |
| SMILES | COC1=C(C=CC(=C1)F)C2=CC(=NC=C2F)NC3=NC=CC(=C3)CS(=N)(=O)C |
| Reference | [1]. Luecking, et al. Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 984. doi:10.1158/1538-7445.AM2017-984 |
